1. © Topadur Pharma AG | May 2018
INNOVATIVE DRUGS FOR SEVERE  WOUND-HEALING  PROBLEMS  IN HOSPITALS
Reto Naef, PhD, MBA
CEO and founder
© Topadur Pharma AG | May 2018

2. two future equity rounds expected exit: 2021 NEXT MILESTONES
The company
Founded: 2009 GmbH, 2015 AG
Employees: 15
FINANCIALS
8.5 Mio equity
1.6 non diluting open
two future equity rounds
expected exit: 2021
NEXT MILESTONES
TOP-N53 end toxicology Q2/18
IND Q3/18
FIH Q4/18
POC Q2/19
Problem & solution:
Chronic non-healing wounds and excessive scar formation
© Topadur Pharma AG | May 2018

3. © Topadur Pharma AG | May 2018
Key people committed to solve the problem
Leadership and board >150 years Pharma R&D
Leadership
Board
Dr. Guido Koch
COO & Development
Dr. Reto Naef CEO &President
Dr. Reinhard Ambros
Prof. Dr. Günther Wess
VC, BD&L
Helmholz, R&D, diabetes
Dr. Hermann Tenor
Medical R&D
Christina Attaalla
Finance, HR, Legal
Dr. Armin Meinzer
Secretary o. B.
Dr. Dominik Escher
Serial founder, deal making
Pascal Brenneisen
HP, investor, legal, market
© Topadur Pharma AG | May 2018

4. Diabetic foot ulcer & chronic wounds
What is the problem?
Diabetic foot ulcer & chronic wounds
Leading cause of
hospitalizations in diabetes
Insufficient local blood circulation
50 million patients
hospitalized p.a.
Huge cost burden
($12 bn p.a.)
Market will double in 15 years
Current Therapies
(limited success)
Negative pressure
Skin substitutes
Oxygen
Growth factors
Regranex (Becaplermin)
1 million foot amputations p.a.
5 year survival 21%
© Topadur Pharma AG | May 2018

5. © Topadur Pharma AG | May 2018
Unique efficacy & excellent tolerability
Our leading drug in development TOP-N53
Increases local blood flow in an unprecidented manner
Convincing results in preclinical wound healing models
Unique potency and efficacy
No visible side effects in animals
Clinical trial starting November 2018
Blockbuster potential
© Topadur Pharma AG | May 2018

6. Regenerative medicine
Past and future milestones
The business case
TOP-N53 DFU project and clinical strategy
TOPADUR
Big Pharma
Drug Discovery
Ongoing grant applications 3.5 Mio. CHF
May 18
2009
2015
2018
2019
2021
TOPADUR
Rare diseases
Regenerative medicine
© Topadur Pharma AG | May 2018

7. Scar & keloid prevention
Topadur’s R&D portfolio
Development drug pipeline and platform
Wound healing
TOP-N53
Scar & keloid prevention
TOP-N44
Out licensing
TOP-N73
Diabetic foot ulcers
Orphan ulcera
Decubitus
Major surgery (incl. bone)
Dental surgery
Patent filed Nov 2015
Burn wounds
Skin fibrosis
Scleroderma
Cosmetic surgery
Patent to be filed Q1 2019
1. Glaucoma (Vistadur)
2. ED - Topical
3. Pulmonary Arterial Hypertension
4. Medical Cosmetics
Patent filed March 2017
2nd Patent to be filed <July 2018
© Topadur Pharma AG | May 2018

8. © Topadur Pharma AG | May 2018
The drug and the patient groups
Overview DFU Wagner classification
Reduce # of amputations
(> 1 Mio/year)
Grade 0
No open
lesion
Grade 1
superficial
lesion
Grade 2
Deep ulcer
Grade 3
abcess,
osteomyelitis
Grade 4
Partial foot
gangreen
Grade 5
Whole foot
gangreen
Topical TOP-N53 SR Hydrogel
TOP-N53 SR Injectable
© Topadur Pharma AG | May 2018

9. © Topadur Pharma AG | May 2018
Financial overview
Financing Strategy
In vitro
profile
2 POC
animal
first in
human
POC
Phase 1/2
Exit
Trade sale
IPO
Orphan 1st launch
DFU
Phase 3
1st launch
TCHF
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Non-diluting financing
Out-licensing
500
1’000
3’500
4’000
190’000
50’000
FTEs 4 8 12 13 14 20 30 45 70
General expenses
-200
-1’800
-3’500
-3’800
-6’400
-8’800
-13’200
19’800
29’700
-44’500
Equity financing
300
2’200
6’100
(3’000)*
10’000
(13’000)**
Company valuation
0.1-2
7-10
19-25
... *
3-4 Mio. Convertable loan after completed toxicology program mid 2018
Depending on non diluting financing **
© Topadur Pharma AG | May 2018

10. © Topadur Pharma AG | May 2018
New venture
Topadur ophthalmic project Vistadur
Reduced occular blood flow
Segment
Current market
Mio $
CAGR%
AMD
7’800 8
Glaucoma
6’500 11
Diabetic retinopathy
2’300 6
Not-treatable
Vistadur targets for drug intervention
treatable
© Topadur Pharma AG | May 2018

11. © Topadur Pharma AG | May 2018
Summary
TOP-N53: Unique potency and efficacy, new dual mode of action
Full pipeline
Experienced leadership team and board
Productive collaborations with academic leaders in their field
Enormous market potential
© Topadur Pharma AG | May 2018

12. DIABETES FOOT BURN WOUNDS TOP-N73 OUT LICENSING
TOP-N TOP-N44
DIABETES FOOT BURN WOUNDS
TOP-N73
OUT LICENSING
HEALTH IS THE MOST IMPORTANT THING
© Topadur Pharma AG | May 2018